| Category | Funding IC | Project Number | Sub Project # | Project Title | PI Name | Org Name | State / Country | Amount |
|
Hodgkin's Disease
|
NCI
|
4R37CA042245-23
|
|
Regulation of replication and latency EBV EBNAs
|
HAYWARD, S
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$367,373
|
|
Hodgkin's Disease
|
NCI
|
5R01CA058853-15
|
|
Regulation of EBV Infection in Epithelial Cells
|
KENNEY, SHANNON
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$278,599
|
|
Hodgkin's Disease
|
NCI
|
5R01CA030356-27
|
|
EBV Genome Expression:Localization of Specific Functions
|
HAYWARD, S
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$330,440
|
|
Hodgkin's Disease
|
NIAID
|
2R01AI018757-26
|
|
Host Immunity to EBV Infection in Vitro and in VIvo
|
THORLEY-LAWSON, DAVID
|
TUFTS UNIVERSITY BOSTON
|
MA
|
$410,729
|
|
Hodgkin's Disease
|
NCI
|
4R37CA012055-36
|
|
Studies of Epstein-Barr Virus
|
MILLER, I.
|
YALE UNIVERSITY
|
CT
|
$451,285
|
|
Hodgkin's Disease
|
NCI
|
2P01CA094237-06
|
0001
|
OVERCOMING TUMOR EVASION MECHANISMS IN HODGKIN DISEASE
|
ROONEY, CLIONA
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$268,054
|
|
Hodgkin's Disease
|
NCI
|
2P01CA094237-06
|
0002
|
THE ROLE AND MECHANISMS OF CD4+ T CELLS IN ANTITUMOR IMMUNITY
|
WANG, RONGFU
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$268,054
|
|
Hodgkin's Disease
|
NCI
|
5R01CA105157-05
|
|
Pathways of Death and Survival in EBV B Cell Lymphomas
|
MARTINEZ, OLIVIA
|
STANFORD UNIVERSITY
|
CA
|
$248,803
|
|
Hodgkin's Disease
|
NCI
|
5R01CA124311-02
|
|
Regulation of Epstein Barr virus reactivation through the co-activators, CBP/p300
|
FLEMINGTON, ERIK
|
TULANE UNIVERSITY OF LOUISIANA
|
LA
|
$254,790
|
|
Hodgkin's Disease
|
NCI
|
5R01CA101795-05
|
|
Novel Strategies for Immunotherapy of Cancer
|
WANG, RONGFU
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$263,284
|
|
Hodgkin's Disease
|
NCI
|
5K23CA113775-03
|
|
Proteosome Inhibition Therapy for Hematologic Malignancy
|
HORTON, TERZAH
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$134,015
|
|
Hodgkin's Disease
|
NCI
|
5R01CA068051-13
|
|
Pathogenesis of Epstein-Barr Virus Infection
|
WANG, FREDERICK
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$407,881
|
|
Hodgkin's Disease
|
NCI
|
5R01CA106159-04
|
|
Role of Epstein-Barr virus LMP1 in lymphoma
|
IZUMI, KENNETH
|
UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT
|
TX
|
$218,727
|
|
Hodgkin's Disease
|
NCI
|
5R21CA129045-02
|
|
Prognostic Genetic Biomarkers for Cancer
|
ONEL, KENAN
|
UNIVERSITY OF CHICAGO
|
IL
|
$122,800
|
|
Hodgkin's Disease
|
NIAID
|
2R01AI041769-11A1
|
|
Cellular Mechanisms of PTLD in Transplant Recipients
|
MARTINEZ, OLIVIA
|
STANFORD UNIVERSITY
|
CA
|
$354,265
|
|
Hodgkin's Disease
|
NCI
|
5R01CA085180-08
|
|
Epstein-Barr Virus LMP-1 Mediated Oncogenicity
|
KIEFF, ELLIOTT
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$726,878
|
|
Hodgkin's Disease
|
NCI
|
2P01CA022443-31
|
0013
|
Mechanisms of Reactivation of Epstein-Barr Virus from Latency to Lytic Replicatio
|
MERTZ, JANET
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$200,142
|
|
Hodgkin's Disease
|
NIAID
|
5R01AI071928-03
|
|
Regulation of Latent-Lytic Switch in EBV by ZEB
|
MERTZ, JANET
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$350,063
|
|
Hodgkin's Disease
|
NCI
|
1K23CA124465-01A2
|
|
Novel Biologic Therapies for Hodgkin's Lymphoma
|
KASAMON, YVETTE
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$140,940
|
|
Hodgkin's Disease
|
NCI
|
5R01CA057152-14
|
|
Immune Dysfunction and AIDS-associated B Cell Lymphoma
|
MARTINEZ-MAZA, OTONIEL
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$279,804
|
|
Hodgkin's Disease
|
NCI
|
5K08CA101934-06
|
|
Notch-Mediated Apoptosis in Human B Cell Malignancies
|
ZWEIDLER-MCKAY, PATRICK
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
TX
|
$136,080
|
|
Hodgkin's Disease
|
NCI
|
2P01CA022443-31
|
0010
|
Inhibiting The Survival And Proliferation Of EBV-Associated Tumor Cells
|
KENNEY, SHANNON
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$233,184
|
|
Hodgkin's Disease
|
NCI
|
2R01CA073507-11A2
|
|
In Vivo Model of Epstein-Barr Virus Latency
|
LONGNECKER, RICHARD
|
NORTHWESTERN UNIVERSITY
|
IL
|
$377,500
|
|
Hodgkin's Disease
|
NCI
|
5R01CA127433-02
|
|
Signal transduction inhibitor therapy for Lymphoma
|
WITZIG, THOMAS
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
MN
|
$330,462
|
|
Hodgkin's Disease
|
NCI
|
5R01CA047006-21
|
|
Epstein-Barr Virus Nuclear Proteins in B Cell Growth Transformation
|
KIEFF, ELLIOTT
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$543,770
|
|
Hodgkin's Disease
|
NCI
|
2R01CA108609-04A2
|
|
Anti-viral DC/NK interactions
|
MUNZ, CHRISTIAN
|
ROCKEFELLER UNIVERSITY
|
NY
|
$283,786
|
|
Hodgkin's Disease
|
NCI
|
1R01CA131027-01A1
|
|
Chimeric T Cell for Therpay of Hodgkin Disease
|
SAVOLDO, BARBARA
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$308,743
|
|
Hodgkin's Disease
|
NCI
|
1R01CA127530-01A1
|
|
The role of protein kinase PKK in BAFF signaling and B-cell malignancies
|
ZHAO, JIYONG
|
UNIVERSITY OF ROCHESTER
|
NY
|
$319,550
|
|
Hodgkin's Disease
|
NCI
|
1R21CA133876-01A1
|
|
Clinical Activity of MGCD-0103 in Hodgkin Lymphoma
|
YOUNES, ANAS
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
TX
|
$250,200
|
|
Hodgkin's Disease
|
NCI
|
1R01CA133063-01A1
|
|
Discovery of New Treatment Options for EBV-associated Lymphoma and PTLD
|
LONGNECKER, RICHARD
|
NORTHWESTERN UNIVERSITY
|
IL
|
$274,204
|
|
Hodgkin's Disease
|
RMAP
|
1R21NS063906-01
|
|
Assay For Inhibitors of Epstein-Barr Virus
|
LIEBERMAN, PAUL
|
WISTAR INSTITUTE
|
PA
|
$140,948
|
|
Hodgkin's Disease
|
NCI
|
1R03CA137828-01
|
|
Hodgkin Lymphoma Consortium: Pooling epidemiologic data for a research resource
|
GLASER, SALLY
|
NORTHERN CALIFORNIA CANCER CENTER
|
CA
|
$72,500
|
|
Hodgkin's Disease
|
NCI
|
5P01CA015396-33
|
0020
|
Hodgkin's Lymphoma Stem Cells
|
AMBINDER, RICHARD
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$353,501
|
|
Hodgkin's Disease
|
NCI
|
5P50CA097274-07
|
0002
|
Signal Transduction Inhibitor Therapy for Lymphoma
|
WITZIG, THOMAS
|
UNIVERSITY OF IOWA
|
IA
|
$309,922
|
|
Hodgkin's Disease
|
NCI
|
5P50CA097274-07
|
0004
|
Regulatory T-Cells in the Tumor Microenvironment of B-Cell Non-Hodgkin
|
ANSELL, STEPHEN
|
UNIVERSITY OF IOWA
|
IA
|
$287,478
|
|
Hodgkin's Disease
|
NCI
|
3R01CA057152-14S1
|
|
Immune Dysfunction and AIDS-associated B Cell Lymphoma
|
MARTINEZ-MAZA, OTONIEL
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$163,086
|
|
Hodgkin's Disease
|
NCI
|
5P01CA016038-35
|
0001
|
Biology of the Epstein-Barr Virus R Transactivator in Human B Cells
|
MILLER, GEORGE
|
YALE UNIVERSITY
|
CT
|
$436,111
|
|
Hodgkin's Disease
|
NCI
|
5P50CA126752-02
|
0001
|
Immunotherapy for Hodgkin's Disease
|
ROONEY, CLIONA
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$245,785
|
|
Hodgkin's Disease
|
NCI
|
5P50CA126752-02
|
0003
|
T Cell Therapy Targeting LMP1 and 2 in EBV+VE Lymphomas
|
GOTTSCHALK, STEPHEN
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$257,740
|
|
Hodgkin's Disease
|
NIAID
|
1R56AI073215-01A1
|
|
Mechanisms of Gene Regulation by EBV EBNA-1 Protein
|
SAMPLE, JEFFERY
|
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
|
PA
|
$379,236
|
|
Hodgkin's Disease
|
NCI
|
5P50CA107399-05
|
0001
|
Anti-CD30 Radioimmunotherapy of Hodgkin's Lymphoma & CD30+ NonHodgkin's Lymphoma
|
RAUBITSCHEK, ANDREW
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
CA
|
$138,679
|
|
Hodgkin's Disease
|
NCI
|
5P50CA107399-05
|
0003
|
Therapy-Related Leukemia Following Autologous Transplantation for Lymphoma
|
BHATIA, RAVI
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
CA
|
$335,563
|
|
Hodgkin's Disease
|
NCRR
|
2P51RR000168-47
|
5588
|
PATHOGENESIS OF EPSTEIN-BARR VIRUS INFECTION
|
WANG, FREDERICK
|
HARVARD UNIVERSITY (MEDICAL SCHOOL)
|
MA
|
$237,907
|
|
Hodgkin's Disease
|
NCRR
|
2M01RR000046-48
|
6996
|
SB-743971 IN PATIENTS WITH NON-HODGKINS
|
VANDEVENTER, HANK
|
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$3,367
|
|
Hodgkin's Disease
|
NCRR
|
5M01RR000188-44
|
7843
|
CLINICAL TRIAL: ADMINISTRATION OF NEOMYCIN RESISTANCE GENE MARKED EBV SPECIFIC C
|
BOLLARD, CATHERINE
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$3,569
|
|
Hodgkin's Disease
|
NCRR
|
5M01RR000188-44
|
7850
|
CLINICAL TRIAL: NEOMYCIN RESISTANCE LMP2A SPECIFIC CYTOTOXIC T-LYMPHOCYTES FOR E
|
BOLLARD, CATHERINE
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$13,162
|
|
Hodgkin's Disease
|
NCRR
|
5M01RR000188-44
|
7851
|
CLINICAL TRIAL: ADMINISTRATION OF LMP2A-SPECIFIC CYTOTOXIC T-LYMPHOCYTES FOLLOW
|
BOLLARD, CATHERINE
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$223
|
|
Hodgkin's Disease
|
NCRR
|
5M01RR000188-44
|
7865
|
CLINICAL TRIAL: ADMINISTRATION OF LMP1- AND LMP2-SPECIFIC CYTOTOXIC T-LYMPHOCYTE
|
GOTTSCHALK, STEPHEN
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$17,538
|
|
Hodgkin's Disease
|
NCRR
|
5M01RR000070-46
|
7965
|
CLINICAL TRIAL: KLH WITH GM-CSF, IN PATIENTS WITH FOLLICULAR NON-HODGKIN'S LYMPH
|
LEVY, RONALD
|
STANFORD UNIVERSITY
|
CA
|
$455
|
|
Hodgkin's Disease
|
NCRR
|
5M01RR010732-14
|
5012
|
CLINICAL TRIAL: A RANDOMIZED PHASE III TRIAL OF ABVD VS STANDFORD V+/- RADIATION
|
RYBKA, WITOLD
|
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
|
PA
|
$4,463
|
|
Hodgkin's Disease
|
NCRR
|
5P41RR013186-11
|
8815
|
DEVELOPMENT OF USER GUIDE & TUTORIAL FOR VIRTUAL CELL SOFTWARE
|
SCHAFF, JAMES
|
UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
|
CT
|
$27,639
|
|
Hodgkin's Disease
|
NIAID
|
1Z01AI000858-09
|
|
Lymphomas And Retroviral Pathogenesis
|
MORSE, HERBERT
|
NIH
|
|
$876,014
|
|
Hodgkin's Disease
|
NCI
|
1Z01BC011070-01
|
|
Hematopathology diagnosis and education
|
JAFFE, ELAINE
|
NIH
|
|
$736,790
|
|
Hodgkin's Disease
|
NCI
|
1Z01SC004002-39
|
|
IL-2IL-15 Cytokine Receptor: Implications for Cancer Therapy and Vaccine Design
|
WALDMANN, THOMAS
|
NIH
|
|
$1,990,761
|
